Cimerli Interchangeable Biosimilar Approved Without Switching Data
Coherus Ranibizumab Rival Will Compete With Lucentis And Byooviz In US
Coherus avoided having to conduct a study in which patients switched back and forth between Cimerli and the reference product Lucentis • Source: Shutterstock
